Remote care for people with low-risk blood clots (DVT or PE)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study enrolls patients identified in the emergency department with low-risk thromboembolic disease (deep vein thrombosis or pulmonary embolism) and provides routine treatment per national guidelines plus a 4G tablet for education, questionnaires, remote consultations and adherence monitoring. Outcomes include feasibility of coordination between hospital physicians and primary care at 6 months and 1 year, plus complication rates, thromboembolism-related hospitalizations, and treatment compliance at those time points. Patients with major bleeding risk, severe comorbidities, renal failure, caval thrombosis, or contraindications to direct oral anticoagulants are excluded. The intervention focuses on remote organization and patient-facing digital support to determine whether it can safely streamline follow-up for low-risk patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients identified in the emergency department with a thromboembolic disease, with a deep vein thrombosis or pulmonary embolism with a low risk of mortality according to recommendations
* affiliated or beneficiary of social protection

Exclusion Criteria:

* patient having a severe obstruction syndrome, a thromboembolic disease already under treatment or a suspicion of thrombocytopenia induced by heparin
* patient with an active hemorrhage or a major risk of hemorrhage, a renal severe failure, comorbidities such as cancer, or the impossibility to organise a consultation or a patient in a non favorable medico-social context
* patient with a caval thrombosis
* patient suffering of a disease at hemorrhagic risk or neurosurgery intervention done in the last month or other surgery in the last 15 days prior to inclusion
* patient with contraindication of direct oral anticoagulants, such as bitherapy with antiplatelet agent, imidazoles, macrolides, antiretroviral treatments or an anti-phospholipid syndrome
* patient that lives in an area not covered by internet
* patient that has no primary care physician
* patient not able to understand the study (language, psychological problem) or not able to read or write
* patient under legal protection

Where it's running

• Centre Hospitalier Eure-Seine
  Évreux, France Recruiting

Study contacts

• Principal investigator: Vincent Eble, MD — CH Eure-Seine
• Study coordinator: Lydia BEN BEKKOU, ARC
• Email: arc2.circe@ch-eureseine.fr
• Phone: +332 32 33 86 75

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How heparins can interfere with argatroban blood tests

  This project will test whether remaining heparin in blood samples changes laboratory measurements of argatroban activity for adults treated with UFH or LMWH.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07302620

• Evaluating flow-diverting stents for treating cerebral aneurysms

  This study is testing two types of stents to see if they can safely and effectively treat cerebral aneurysms in patients across several hospitals in Spain.

  Recruiting at 11 sites Hospital Universitario Central de Asturias · A Coruña and 10 other locations · NCT06201598

• Investigating Clonal Hematopoiesis and Neutrophil Extracellular Traps in Venous Thrombosis

  This study is trying to see if certain blood changes are linked to repeated blood clots in younger people who don’t have the usual risk factors.

  Recruiting at 3 sites University Hospital, Bordeaux · Bordeaux and 6 other locations · NCT05711173

• Evaluating endovascular treatment for blood clots in the legs

  This study is testing new treatments for blood clots in the legs to see if they are safe and effective for patients with certain types of blockages.

  Recruiting First People's Hospital of Hangzhou · Hangzhou, Zhejiang · NCT04861506

• Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers

  This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.

  Recruiting Medical University of Gdansk · Gdansk, Pomeranian Voivodeship · NCT07270263

• Monitoring adults after venous thromboembolism

  This project tests whether using bleeding-and-recurrence risk scores together with multidisciplinary thrombosis meetings helps guide anticoagulant treatment for adults hospitalized with venous thromboembolism.

  Recruiting University Hospital, Rouen · Rouen · NCT07016542

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.